Novacta raises £13.1 million as Celtic takes majority stake
This article was originally published in Scrip
Executive Summary
Celtic Pharma's second fund, Celtic Pharma Holdings II LP (CP2), has made its first major investment, becoming the majority shareholder of antibiotic developer Novacta Biosystems.